About CRISPRIL

Aims & Objectives

Towards a Safe and Accurate Genome Editing

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a groundbreaking and leading technology in the biotech and health industry in recent years. The ability to generate precise genomic modifications in a relatively simple and efficient manner revolutionized the ability of scientists to study various types of diseases, develop improved crops and livestock and understand genetic processes.
Harnessing CRISPR in medicine and agriculture would ultimately lead to the development of safer and cheaper solutions worth billions of dollars and address some of the critical challenges of our time.
Although CRISPR-Cas is considered convenient for specific targeting of the desired trait, it still faces several challenges, preventing more extensive use and products in the markets.

These challenges include:
(i) Accidental “off-target” modification
(ii) Low “on-target” efficiency requiring repeated trials
(iii) Inaccurate tools for validating the planned modifications

The CRISPRIL consortium was established to address these challenges. The CRISPRIL consortium aims to develop an artificial intelligence-based system, “GOGENOME,” providing improved genome-editing workflows with high accuracy and efficacy.

Expected Outcome

GOGENOME – An end-to-end platform for Genome Editing

  • The system is expected to include the computational design of on-target DNA modification, with minimal accidental, off-target modifications, improve modification efficiency and provide an accurate measuring tool to ensure the desired modification was made
  • This system intends to be effective in multi-species, including human, plants, and certain animals relevant to market segments in pharma, agriculture, and aquaculture


Our Targets:

  • Improve “on-target” accuracy
  • Increase “on-target” efficiency
  • Decrease “off-target” events
  • Generate a globally-unique multi-species CRISPR dataset
  • Support genome editing for a wide range of valuable species in the life sciences industry
  • Support multiple workflows
  • Increase CRISPR utilization by the industry towards bringing more products to the market

Click image to enlarge

Target Gene

Choose your genomic loci for editing:
Genomes, Cell types, Genetic element

Recommended gRNAs & Primers

Support Cas9, Cas12a , other

Editing Type

Choose your desired type of modification:
Knock-Out, Knock-In, HDR, other

Lab Protocol

Standardize protocol
Meta data & data
Cloud-based collection support

Editing System

Choose your preferred editing Cas system:
Cas9, Cas12a, other

Editing Analysis Protocol

On target & Off target

Work Groups

The CRISPRIL participants are organized into four major groups, which are responsible for:

Work Group 1 – gRNA design prediction
Work Group 2 – Genome editing analysis and standardization
Work Group 3 – Group of genome editing users from Pharma and Agriculture
Work Group 4 – Computational infrastructure development

Workgroups 1, 2, and 4 develop the GOGENOME machines, while group 3 uses the designed systems to perform editing experiments and deliver editing datasets to support artificial intelligence modules training and improvement.

Working Process

Genome Editing Planning

Users select genomic loci to be edited & type of editing

Genome Editing Analysis

Editing efficiencies &  profile are called using computational measurement machine

Genome Editing Design

AI based prediction of guides RNAs & Amplicon’s primers designed using proprietary machine

Genome Editing Measuring

Amplicon’s undergo sequencing using NGS

Genome Editing Performance

Editing using standardized protocols and language. Data collection using cloud-based system

Working Process

Click image to enlarge